<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-17 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-17</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-17</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-399c2545e41bbf9376f97190168917e1d1807fb6</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/399c2545e41bbf9376f97190168917e1d1807fb6" target="_blank">Targeting Genomic Alterations in Squamous Cell Lung Cancer</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> In this review, potentially targetable genes or pathways in squamous cell lung cancer are emphasized in relation to available therapeutic agents in development or active clinical trials and this organization of data will provide a framework for development for clinical investigation.</p>
                <p><strong>Paper Abstract:</strong> Squamous cell lung cancer causes approximately 400,000 deaths worldwide per year. Identification of specific molecular alterations, such as activating mutations in the epidermal growth factor receptor kinase and echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase fusions have led to significant therapeutic gains in patients with adenocarcinoma. However, meaningful therapeutic gains based on the molecular pathobiology of squamous cell lung cancer have not yet been realized. A comprehensive genomic characterization of 178 cases of squamous cell lung cancer has recently been reported. Squamous cell lung cancer appears to be characterized by a broader and more complex group of genomic alterations than adenocarcinoma. In this review, potentially targetable genes or pathways in squamous cell lung cancer are emphasized in relation to available therapeutic agents in development or active clinical trials. This organization of data will provide a framework for development for clinical investigation. Squamous cell lung cancer appears to be characterized by not only driver mutations in candidate genes but also gene copy number alterations resulting in tumor proliferation and survival. Better understanding of these genetic alterations and their use as therapeutic targets will require broad collaboration between industry, government, the cooperative groups, and academic institutions with the ultimate goal of rapid translation of scientific advancement to patient benefit.</p>
                <p><strong>Cost:</strong> 0.022</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e17.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e17.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activating kinase-domain mutations in EGFR are canonical oncogenic drivers in lung adenocarcinoma that confer sensitivity to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating mutations (kinase domain mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK -> RAS/MAPK and PI3K pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical responses to targeted therapy; clinical trials; literature reports</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Activating mutations sensitize tumors to EGFR TKIs (erlotinib, gefitinib) and improve response rates and progression-free survival.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in never-smokers and East Asian populations (as cited); predictive of response to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Sensitive to EGFR TKIs (erlotinib, gefitinib); established targeted therapy in adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>targeted sequencing / clinical molecular testing (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e17.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Echinoderm microtubule-associated protein-like 4 — Anaplastic lymphoma kinase fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ALK gene fusions (classically EML4-ALK) are recurrent oncogenic gene rearrangements in lung adenocarcinoma that confer sensitivity to ALK inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene fusion (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK / RTK -> downstream signaling (RAS/MAPK, PI3K)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical responses to targeted therapy; clinical trials (crizotinib)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>ALK fusions drive kinase activity and tumor dependence; tumors respond clinically to ALK inhibition (crizotinib).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Described in adenocarcinoma; actionable biomarker guiding therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Responds to ALK inhibitors (crizotinib) and other ALK-targeted agents.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>fusion detection (FISH, sequencing, transcriptome methods)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e17.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 gene rearrangements are oncogenic fusions observed in lung adenocarcinoma and represent clinically targetable events.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 gene rearrangement / fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature reports and clinical targeting (mentioned as important clinical targets)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Fusion leads to constitutive kinase activity (implied by clinical targeting literature).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Reported in lung adenocarcinoma as actionable rearrangement.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable with ROS1/ALK inhibitors (clinical relevance noted).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>rearrangement/fusion detection (transcriptome sequencing / FISH)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e17.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET gene rearrangements (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>RET fusions (such as KIF5B-RET) are recurrent, targetable gene rearrangements identified in lung adenocarcinoma by genomic/transcriptomic sequencing.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET gene fusion (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome/transcriptome discovery (literature citation); considered clinically targetable</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Fusion leads to activated kinase signaling (implied by discovery and targetability).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Described in adenocarcinoma (reported from whole-genome/transcriptome sequencing).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential target for RET-directed therapies (clinical relevance cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>whole-genome and transcriptome sequencing (as cited)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e17.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS (KRAS GTPase) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS activating mutations are canonical drivers in lung adenocarcinoma (part of RAS pathway) and are referenced as part of the landscape of driver oncogenes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS activating mutations (e.g., codon 12/13)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS -> RAF -> MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention / mutual exclusivity context (cited in discussion of other alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Classical oncogenic activation of RAS-MAPK signaling (well-established in literature; mentioned here in context).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>KRAS historically hard to target; mentioned as part of mutational landscape.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>sequencing (implied by references)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e17.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF (B-Raf) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BRAF mutations are oncogenic alterations in the RAF family reported in lung cancer and cited in this paper as one of the targetable drivers (noted frequency for squamous in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF mutation</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAF -> MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention as driver; frequency given for squamous in paper (4%)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Activating BRAF mutations cause MAPK pathway activation (well-established; cited indirectly).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>BRAF is a clinically actionable MAPK-pathway oncogene in lung cancer (implied).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>sequencing (implied)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e17.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET (hepatocyte growth factor receptor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MET activation via increased expression, amplification, or mutation can drive lung cancer biology and contributes to acquired resistance to EGFR inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET amplification / overexpression; somatic MET mutation (reported in NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>amplification; increased expression; point mutation (somatic) in some reports</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET / RTK -> PI3K, RAS-MAPK, STAT3 pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>81.3% (increased expression; value reported in table)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>immunohistochemistry for expression; copy-number studies; case reports of response to MET/ALK inhibitor (crizotinib); clinical trial data</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>MET activation stimulates proliferation, motility, angiogenesis and invasiveness via PI3K, RAS-MAPK, STAT3; MET amplification mediates acquired resistance to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>High MET expression associated with poor prognosis and brain metastases; MET amplification seen in up to ~20% of EGFR TKI–treated resistant tumors (reported).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by MET inhibitors/antibodies (e.g., crizotinib shows activity in MET-amplified case; MetMAb combined with erlotinib showed benefit in a trial).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>immunohistochemistry (expression), copy-number assays/FISH (amplification), sequencing (mutations); referenced case report and trials</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e17.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PIK3CA (p110α catalytic subunit of PI3K)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PIK3CA harbors hotspot activating mutations and is frequently amplified; alterations activate PI3K-AKT-mTOR signaling and are found in lung cancers including adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA mutation (helical/kinase domain) and PIK3CA amplification (3q26.3)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating); copy-number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA / PI3K -> AKT/mTOR pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>mutation ~1.5% (table); amplification ~6% (table)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (mutational and copy-number analyses); co-occurrence studies with EGFR; preclinical sensitivity to PI3K inhibitors; early-phase trials</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Mutations/amplifications activate PI3K-AKT signaling; amplifications more frequent than mutations; associated with resistance to EGFR TKIs when co-occurring.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutations can co-occur with EGFR mutations; PIK3CA activation implicated in EGFR-TKI resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>PI3K inhibitors (BKM120, BYL719, others) in trials; combinations with other agents being explored.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>sequencing for mutations; SNP array / copy-number analysis / FISH for amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e17.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PTEN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PTEN (phosphatase and tensin homolog)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss-of-function mutations or inactivation of PTEN remove negative regulation of PI3K signaling, promoting tumor survival and therapy resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PTEN mutation / loss of function</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation / deletion (inactivation)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PTEN / negative regulator of PI3K -> AKT/mTOR pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1.7% (table reports frequency in adenocarcinoma)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical sequencing studies; functional studies cited regarding impact on EGFR-TKI sensitivity</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>PTEN inactivation increases PI3K-AKT-mTOR activity; contributes to EGFR-TKI resistance by uncoupling EGFR from downstream signaling; PTEN-deficient tumors more sensitive to mTOR inhibitors in preclinical studies.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More frequent in smokers and more common in squamous than adenocarcinoma overall in cited analyses (paper discusses NSCLC frequencies).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential sensitivity to PI3K/AKT/mTOR pathway inhibitors; a PTEN-deficient–selected drug (GSK2636771) is being studied.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>sequencing / mutation analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e17.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AKT1 E17K</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AKT1 E17K mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A transforming hotspot mutation in the AKT1 pleckstrin homology domain (E17K) that constitutively activates AKT signaling, observed at low frequency in NSCLC subsets.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>AKT1 E17K (glutamic acid to lysine at codon 17)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>AKT1 / PI3K-AKT-mTOR pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% (table reports 0% in adenocarcinoma) ; overall NSCLC occurrence 1-2% (text)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical tumor sequencing; functional transformation assays (cited from literature)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Mutation constitutively activates kinase, transforms cells in culture and induces leukemia in mice (from cited foundational work).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in a subset of NSCLC; rare event within lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>AKT inhibitors (GDC-0068, MK-2206) in clinical trials; potential target in tumors harboring E17K.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>high-resolution melting / sequencing (as cited)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e17.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LKB1 / STK11</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Liver kinase B1 (also called STK11)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor-suppressor kinase frequently inactivated in lung cancer; loss alters AMPK/mTOR signaling and cooperates with other oncogenes to promote tumor progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>LKB1 mutation / deletion (loss of function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / deletion (loss of function)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>LKB1 -> AMPK -> mTOR pathway (tumor suppressor)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>34% (table reports 34% in adenocarcinomas in the cited analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>sequencing of clinical specimens; functional studies in mouse models (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>LKB1 loss suppresses AMPK leading to increased mTOR signaling; cooperates with KRAS to enhance tumor growth/metastasis in mouse models; associated proteomic changes suggest IGF1R upregulation.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutations more common in Whites than Asians; involved in early tumorigenesis and metastasis.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Suggests potential combination strategies targeting IGF1R and mTOR pathways in LKB1-mutant tumors; no trials yet reported in paper for combinations.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>144 (number of human NSCLC specimens in cited study where frequencies reported)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>sequencing / clinical specimen analysis; reverse phase protein array for pathway analysis (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e17.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FGFR1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Fibroblast growth factor receptor 1</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>FGFR1 is recurrently amplified in lung cancers (particularly squamous) but also present at low frequency in adenocarcinoma and can confer dependence susceptible to FGFR inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FGFR1 amplification (8p11-12)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>FGFR1 / RTK -> downstream proliferative signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3.4% (table reports frequency in adenocarcinoma)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>SNP array and FISH copy-number analyses; cell-line sensitivity studies to FGFR inhibitors; early clinical trial response in FGFR1-amplified patient</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>FGFR1-amplified cell lines are growth-dependent on FGFR1 and sensitive to FGFR inhibitors (PD173074, NVP-BGJ398) in vitro and in select patient.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Amplification enriched in squamous histology, but present at lower frequency in adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>FGFR inhibitors (NVP-BGJ398, AZD4547, E-3810) in clinical trials; one FGFR1-amplified lung cancer showed response to NVP-BGJ398.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SNP array copy-number analysis; FISH; cell line assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e17.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e17.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SOX2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SRY (sex determining region)-box 2</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>SOX2 is a lineage-survival transcription factor that is recurrently amplified/overexpressed (3q26.33) in lung squamous cancers and is also expressed in a subset of adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting genomic alterations in squamous cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SOX2 amplification and overexpression (3q26.33)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number amplification; overexpression</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SOX2 (transcription factor; lineage survival oncogene)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>SOX2 increased expression ~21% in adenocarcinoma (table cites 21%); amplification ~20% in squamous (not adenocarc-specific)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic amplification analyses; IHC expression studies; mouse models showing oncogenicity</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>SOX2 overexpression promotes cell migration, anchorage-independent growth, survival; overexpression oncogenic in mice (about 50% developed lung cancer in cited model).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Strong/diffuse expression in many squamous cases; present in subset of adenocarcinomas and neuroendocrine tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No clinical targeting agents yet; considered lineage-survival oncogene.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>genomic amplification (copy-number), IHC for protein expression, mouse models</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting Genomic Alterations in Squamous Cell Lung Cancer', 'publication_date_yy_mm': '2013-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The transcriptional landscape and mutational profile of lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Genotypic and histologic evolution of lung cancers acquiring resistance to EGFR inhibitors <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>